SWK Holdings Corp (SWKH) FY2024 10-K Annual Report
SWK Holdings Corp (SWKH) 10-K annual report for fiscal year 2024, filed with SEC EDGAR on Mar 20, 2025. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
SWK Holdings Corp FY2024 10-K Analysis
Business Overview
- • Core business model: dual segments of specialty finance in life sciences and pharmaceutical development/manufacturing
- • Pharmaceutical Development segment entered asset sale process with March 2024 exclusive option to sell Enteris BioPharma assets by January 2026, classified as held for sale as of Dec 31, 2024
Management Discussion & Analysis
- • Revenue $45.0M, up $7.2M YoY; Finance Receivables $4.8M increase, Pharmaceutical Development $2.4M increase
- • Net income $13.5M, down $2.4M YoY; interest expense rose to $4.7M from $1.8M; provision for credit losses increased to $12.8M
Risk Factors
- • Regulatory risk: LIBOR transition impacted by the Adjustable Interest Rate (LIBOR) Act of 2022, with synthetic U.S. dollar LIBOR continuing until September 2024
- • Macroeconomic risk: Silicon Valley Bank closure by California Department of Financial Protection and Innovation on March 10, 2023, impacting financial services liquidity
SWK Holdings Corp FY2024 Key Financial MetricsXBRL
Revenue
$4M
▲ +200.8% YoY
Net Income
$13M
▼ -15.1% YoY
Operating Margin
320.4%
▼ -89839bp YoY
Net Margin
373.0%
▼ -94870bp YoY
ROE
4.7%
▼ -100bp YoY
Total Assets
$332M
▼ -0.6% YoY
EPS (Diluted)
$1.08
▼ -13.6% YoY
Operating Cash Flow
$23M
▲ +54.8% YoY
Source: XBRL data from SWK Holdings Corp FY2024 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on SWK Holdings Corp
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.